Matthieu Cornet

Matthieu Cornet

Auto-generated profile, based on publicly available information

Matthieu Cornet

Mines Paris PSL, Institut Curie, INSERM U900, Institut Necker Enfants Malades

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Pediatric Pulmonology
Verified
Journal Article
Open access
MCMatthieu Cornet
Matthieu Cornet
GRGeneviève Robin
Geneviève Robin
FCFabiana Ciciriello
Fabiana Ciciriello
TBTiphaine Bihouee
Tiphaine Bihouee
CMChristophe Marguet
Christophe Marguet
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
Introduction: Clinical trials for CFTR modulators consider mean changes of clinical status at the cohort level, and thus fail to assess the heterogeneity of the response. We aimed to study the different response profiles to lumacaftor‐ivacaftor according to age in children with cystic fibrosis (CF).Methods: A mathematical framework, including principal component analysis, data clustering, and data completion, was applied to a multicenter cohort of 112 children aged 6–18 years, treated with lumacaftor‐ivacaftor. Studied parameters at baseline and 6 months included body mass index (BMI), number of days of antibiotics (ATB), Sweat test (ST), forced expiratory volume in 1 s expressed in percentage predicted (ppFEV1), forced vital capacity (ppFVC), and forced expiratory flow at 25%–75% of FVC (ppFEF25–75).Results: Change in ppFEV1 was the most significant parameter in characterizing response heterogeneity among the 12–18‐year‐old patients. Patients with minimal changes in ppFEV1 were further separated by change in BMI and ATB course. In the 6–12‐year‐old children both BMI and ppFEV1 evolution were the most relevant. ST change was not associated with a clinical response.Conclusions: Change in ppFEV1, BMI, and ATB course are the most relevant outcomes to discriminate clinical response profiles in children treated with lumacaftor‐ivacaftor. Prepubertal and pubertal children display different response profiles.


25 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMatthieu Najm
Matthieu Najm
MCMatthieu Cornet
Matthieu Cornet
LALuca Albergante
Luca Albergante
Andrei ZinovyevAndrei Zinovyev
Andrei Zinovyev
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
LMLoredana Martignetti
Loredana Martignetti
The efficiency of analyzing high-throughput data in systems biology has been demonstrated in numerous studies, where molecular data, such as transcriptomics and proteomics, offers great opportunities for understanding the complexity of biological processes. One important aspect of data analysis in systems biology is the shift from a reductionist approach that focuses on individual components to a more integrative perspective that considers the system as a whole, where the emphasis shifted from differential expression of individual genes to determining the activity of gene sets. Here, we present the rROMA software package for fast and accurate computation of the activity of gene sets with coordinated expression. The rROMA package incorporates significant improvements in the calculation algorithm, along with the implementation of several functions for statistical analysis and visualizing results. These additions greatly expand the package’s capabilities and offer valuable tools for data analysis and interpretation. It is an open-source package available on github at: www.github.com/sysbio-curie/rROMA . Based on publicly available transcriptomic datasets, we applied rROMA to cystic fibrosis, highlighting biological mechanisms potentially involved in the establishment and progression of the disease and the associated genes. Results indicate that rROMA can detect disease-related active signaling pathways using transcriptomic and proteomic data. The results notably identified a significant mechanism relevant to cystic fibrosis, raised awareness of a possible bias related to cell culture, and uncovered an intriguing gene that warrants further investigation. Contact: loredana.martignetti@curie.fr

25 November 2022 in Skin Health and Disease
Verified
Journal Article
Open access
MCMatthieu Cornet
Matthieu Cornet
TNThao Nguyen-Khoa
Thao Nguyen-Khoa
MKMairead Kelly-Aubert
Mairead Kelly-Aubert
VJVincent Jung
Vincent Jung
FCFrédérique Chedevergne
Frédérique Chedevergne
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
Background: A high proportion of patients with Cystic Fibrosis (CF) also present the rare skin disease aquagenic palmoplantar keratoderma. A possible link between this condition and absence of a functional CF Transmembrane conductance Regulator protein in the sweat acinus and collecting duct remains unknown. Methods: In-depth characterization of sweat proteome profiles was performed in 25 CF patients compared to 12 healthy controls. A 20 μL sweat sample was collected after pilocarpine iontophoresis and liquid chromatography tandem mass spectrometry (LC-MS/MS) proteomic analysis was performed. Results: Sweat proteome profile of CF patients was significantly different from that of healthy subjects with 57 differentially expressed proteins. Cystic Fibrosis sweat proteome was characterized by an increase in 25 proteins including proteases (Kallikrein 7 and 13, Phospholipase B domain containing 1, Cathepsin A L2 and B, Lysosomal Pro-X carboxypeptidase); proinflammatory proteins (Annexin A2, Chitinase-3-like protein 1); cytochrome c and transglutaminases. Thirty-two proteins were downregulated in CF sweat including proteases (Elastase 2), antioxidative protein FAM129 B; membrane-bound transporter SLC6A14 and regulator protein Sodium-hydrogen antiporter 3 regulator 1. Conclusion: This study is the first to report in-depth characterization of endogenous peptides in CF sweat and could help understand the complex physiology of the sweat gland. The proteome profile highlights the unbalanced proteolytic and proinflammatory activity of sweat in CF. These results also suggest a defect in pathways involved in skin barrier integrity in CF patients. Sweat proteome profile could prove to be a useful tool in the context of personalized medicine in CF.

7 April 2026
Verified
Thesis
Closed access
MCMatthieu Cornet
Matthieu Cornet
La mucoviscidose est une maladie provoquée par une mutation d’un gène produisant une protéine l’absence ou le dysfonctionnement entraine des lésions au niveau des poumons et un déclin des fonctions respiratoires. Le pronostic des patients porteurs de la mutation la plus courante a récemment été grandement amélioré grâce à la mise au point de nouvelles thérapies. Cependant, la réponse à ces traitements n’est pas homogène parmi les patients, et leur mécanisme d’action n’est pas entièrement compris. En particulier, nous ne disposons pas de marqueur biologique ou clinique qui fasse consensus pour mesurer l’effet d’un traitement. L’objectif de cette thèse a été de caractériser les réponses cliniques à ces thérapies, en particulier chez les jeunes patients, ainsi que de mieux comprendre leurs mécanismes d’action au niveau cellulaire.

17 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMatthieu Najm
Matthieu Najm
LMLoredana Martignetti
Loredana Martignetti
MCMatthieu Cornet
Matthieu Cornet
MKMairead Kelly-Aubert
Mairead Kelly-Aubert
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
VSVéronique Stoven
Véronique Stoven
Background: Cystic Fibrosis (CF) is a monogenic disease caused by mutations in the gene coding the Cystic Fibrosis Transmembrane Regulator (CFTR) protein, but its overall physio-pathology cannot be solely explained by the loss of the CFTR chloride channel function. Indeed, CFTR belongs to a yet not fully deciphered network of proteins participating in various signalling pathways. Methods: We propose a systems biology approach to study how the absence of the CFTR protein at the membrane leads to perturbation of these pathways, resulting in a panel of deleterious CF cellular phenotypes. Results: Based on publicly available transcriptomic datasets, we built and analyzed a CF network that recapitulates signalling dysregulations. The CF network topology and its resulting phenotype was found to be consistent with CF pathology. Conclusion: Analysis of the network topology highlighted a few proteins that may initiate the propagation of dysregulations, those that trigger CF cellular phenotypes, and suggested several candidate therapeutic targets. Although our research is focused on CF, the global approach proposed in the present paper could also be followed to study other rare monogenic diseases.